CymaxTM Human IL-7 ELISA Kit
- Known as:
- CymaxTM Human Interleukin-7 Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- LF-EK0261
- Product Quantity:
- 1
- Category:
- Elisa Kits
- Supplier:
- Abfron
- Gene target:
- CymaxTM Human IL-7 ELISA Kit
Related genes to: CymaxTM Human IL-7 ELISA Kit
- Gene:
- IL7 NIH gene
- Name:
- interleukin 7
- Previous symbol:
- -
- Synonyms:
- IL-7
- Chromosome:
- 8q21.13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-10-12
- Date modifiied:
- 2016-10-11
- Gene:
- IL7R NIH gene
- Name:
- interleukin 7 receptor
- Previous symbol:
- -
- Synonyms:
- CD127, IL7RA
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2019-04-23
Related products to: CymaxTM Human IL-7 ELISA Kit
Related articles to: CymaxTM Human IL-7 ELISA Kit
- First-generation cancer immunotherapies, such as high-dose interleukin-2 (IL-2), have demonstrated clinical efficacy, but are limited by significant systemic toxicities due to their broad expression of cytokine receptors. This has driven the iterative development of targeted cytokine delivery strategies. Early efforts focused on receptor-biased IL-2 variants designed to attenuate or abrogate IL-2 receptor α (IL-2 Rα/CD25) binding. Subsequently, the concept of "-targeting" has emerged as a strategy to deliver cytokines to specific immune cell populations, enhancing anti-tumor responses while mitigating systemic toxicity. This review highlights key common γ-chain cytokines (IL-2, IL-7, IL-15, and IL-21) as well as IL-12, providing an overview of their structures, receptors, as well as their distinct T cell functions. Furthermore, we specifically focus on the current landscape of engineered cytokine variants that facilitate targeted cytokine delivery in to specific T cells. By successfully restricting cytokine activity to specific T cell populations, -targeting approaches represent a promising strategy in the field, enabling efficient immunotherapies with improved tolerability and enhanced anti-tumor responses. - Source: PubMed
Publication date: 2025/11/14
Pousse LaurèneManchala AmritaKlein ChristianCodarri Deak Laura - Myasthenia gravis (MG) lacks disease-specific biomarkers that can support monitoring of disease activity or guide treatment decisions. This study aimed to validate serum inflammatory proteins as MG-specific biomarkers by comparing their specificity to controls and individuals with other autoimmune neurological disorders, including multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP). - Source: PubMed
Bhandage Amol KHoffmann SarahDusemund CarlaStascheit FraukeHuang Yu-FangEriksson NiclasGabrysch KatjaMeisel AndreasPunga Anna Rostedt - For drug-susceptible TB, the WHO-endorsed first-line regimen (isoniazid, rifampicin, ethambutol, pyrazinamide) remains the global reference. Therapy must always be tailored to drug susceptibility, especially in MDR- and XDR-TB. HIV-associated mycobacterial infections-including (TB), disseminated complex (MAC), and Mycobacterium ()-remain leading causes of morbidity and mortality in people living with HIV (PLWH). TB continues to account for the highest burden of AIDS-related deaths worldwide, while MAC and leprosy complicate care in advanced immunosuppression. This review synthesizes current evidence on epidemiology, clinical features, and management challenges of HIV-mycobacterial co-infections. We discuss drug-susceptible and drug-resistant TB therapies, drug-drug interactions with antiretroviral therapy (ART), and the clinical impact of immune reconstitution inflammatory syndrome (IRIS). Beyond established regimens, we highlight host-directed strategies such as metformin, glutathione augmentation, mTOR modulation, and vitamin D; immunotherapies including interferon-γ, GM-CSF, and IL-7; and therapeutic vaccines (M72/AS01E, MTBVAC, VPM1002) as promising adjuncts. Distinct from guideline-focused overviews, this review emphasizes non-tuberculous mycobacterial disease (NTM, including MAC) and leprosy in PLWH and synthesizes host-directed and adjunctive strategies with their translational prospects, including ART compatibility and IRIS. By integrating TB, NTM, and leprosy across the HIV care continuum, we highlight opportunities not treated in detail elsewhere-particularly HDT-enabled approaches and implementation considerations in PLWH. - Source: PubMed
Publication date: 2025/10/23
Nikjeh OmidRejali SeyedehparmisSasaninia KayvanVenketaraman Vishwanath - Type 2 diabetes mellitus (T2DM) is a complicated metabolic condition categorized by insulin resistance, decreased insulin secretion or both. The current study emphasizes the involvement of cytokines particularly interleukin-7 (IL-7), in the pathophysiology of T2DM, which is implicated in immune control and metabolic processes. This research aims to examine the relationship among IL-7 serum concentrations and insulin resistance markers in T2DM individuals, with the goal of determining IL-7's potential as a novel diagnostic marker for this condition. - Source: PubMed
Gharib Amal FHassan Asmaa FSaber TaisirAl-Qurashi Shooq HAl-Thobiti Ghala MAl-Tuwairqi Elaf MAl-Ghamdi Shroog MAlghamdi BashayerAl-Qahtani Norah MKaram Rehab A - Histotripsy was an innovative, non-invasive ultrasound-based technology that mechanically disrupts liver tumour tissues at cellular level through acoustic cavitation. It offered precise swith minimal collateral damage. This study evaluated the safety and efficacy of this novel treatment with biomolecular analysis. - Source: PubMed
Publication date: 2025/11/10
Chan Albert CyLau Vince WhWong Gordon TcChan Y WMan KwanNg L YMa HuanhuanHusain AbdullahNg Irene Ol